SMA at Eurordis’ multi-stakeholder symposium in Brussel

to improve patient access to rare disease therapies

Themselves with just 20% of patients across Europe accessing today’s only therapy, Spinraza™. Although some countries benefit from full access, others, not at all. SMA Europe